yeah, i got this feeling too. the drug companies are desperate to make money off of alzheimer's, but the disease is too obstinate to go along with their wishes

yeah, i got this feeling too. the drug companies are desperate to make money off of alzheimer's, but the disease is too obstinate to go along with their wishes unless they juke the stats. improving cognitive function is very difficult under any circumstance. making a drug that alters a biomarker reliably is, in comparison, very easy. of course, if the biomarker doesn't have a strong correlate to health, it won't help the patient. but they would prefer to sell drugs that "work" without improving the patient's quality of life if it is between that and not selling any drugs. the other reason that these interventions are always so focused on "early" or "preclinical" alzheimer's is because that's when the patient's brain is still more neurotypical than not. as the disease progresses, i get the feeling that many of the normal rules of thumb regarding brain function and drug action in the brain start to fall through, which makes therapy development far harder.